Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Corticosteroids|Corticosteroid]] (6) ·
[[:Category:Analgesics|Analgesic]] (4) ·
[[:Category:Antibacterials|Antibacterial]] (3) ·
[[:Category:Glucocorticoids|Glucocorticoid]] (3) ·
[[:Category:Insulins|Insulin]] (3) ·
Anti-CGRP ligand monoclonal antibody (2) ·
[[:Category:Antifungals|Antifungal]] (2) ·
[[:Category:Antineoplastics|Antineoplastic]] (2) ·
[[:Category:Biologics|Biologic]] (2) ·
[[:Category:DMARDs|DMARD]] (2) ·
[[:Category:Immunosuppressants|Immunosuppressant]] (2) ·
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]] (2) ·
[[:Category:Mealtime_insulins|Mealtime (bolus) insulin]] (2) ·
[[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]] (2) ·
[[:Category:Topical_antifungals|Topical antifungal]] (2)
mechanism:
None (31) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG2 monoclonal antibody binding the CGRP receptor (not the peptide); blocks CGRP-mediated vasodilation and nociceptive signaling (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Tropane alkaloids: hyoscyamine (dominant; the racemic form is atropine), scopolamine. Competitive muscarinic antagonism. (1) ·
'"`UNIQ--vote-00000015-QINU`"' The favorable pregnancy safety profile and the dual mechanism support its first-line role in pregnancy-associated hypertension and in hypertensive emergencies where rapid, controllable BP reduction is needed'"`UNIQ--ref-00000016-QINU`"'. (1) ·
'"`UNIQ--vote-00000019-QINU`"' Once-daily dosing is a clinical advantage over short-half-life NSAIDs'"`UNIQ--ref-0000001A-QINU`"'. (1) ·
'"`UNIQ--vote-0000001D-QINU`"' Major Beers-list concern in elderly patients for cognitive and fall risks. CYP2D6 substrate. At massive overdose, also produces sodium channel blockade with cardiac toxicity'"`UNIQ--ref-0000001E-QINU`"'.
'"`UNIQ--effect-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-00000584-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Ultra-rapid formulations (Lyumjev) add treprostinil and citrate to accelerate absorption further'"`UNIQ--ref-00000585-QINU`"'. (1) ·
'"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) ·
'"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) ·
'"`UNIQ--vote-00001014-QINU`"' Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. The dipropionate, valerate, and augmented dipropionate ester forms determine topical potency (high to super-high)'"`UNIQ--ref-00001015-QINU`"'. (1) ·
'"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1) ·
'"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)
uses:
starting dose:
preparations:
routes: (Click arrow to add another value)
onset:
None (1) ·
1-2 hours (1) ·
10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) ·
15-30 minutes (oral); 1-2 minutes (IV) (1) ·
30-60 minutes (oral); 5 minutes (IV); 15-30 minutes (IM) (1) ·
30-60 minutes (oral); slower for topical (1) ·
5-10 minutes (IV); 30 minutes (oral IR); slower for ER and rectal (1) ·
<1 minute (IV); 1-2 minutes (infiltration); 30+ minutes (patch on adult skin, faster on thinner pediatric skin) (1) ·
Analgesic effect within hours; full anti-inflammatory effect over 1-2 weeks (1) ·
Anticonvulsant effect within days at therapeutic plasma level; rapid titration possible (1) ·
BP effect within hours (oral); 5-10 minutes (IV) (1) ·
Caries reduction over months to years of consistent use (1) ·
Clinical and mycologic cure follows the full course; nail clearance over months of regrowth (1) ·
Days (2) ·
Days for calcium effect; weeks for PTH suppression (1) ·
Days for dermatophyte clearance; nail clearance over months (1) ·
Hours (5) ·
Hours to days (1) ·
Hours to days for inflammation; substantial improvement within 1 week (1) ·
Inhaled: bronchial effect 1-2 weeks; nasal: symptom relief 12-24 hours; topical: hours (1) ·
Intranasal: symptom relief 12-24 hours; inhaled: bronchial effect 1-2 weeks (1) ·
LDL reduction ~50-60% from baseline at 1-2 weeks (1) ·
Minutes (1) ·
Onset of preventive effect over weeks; some patients respond after first dose (1) ·
Over weeks (2) ·
Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks (1) ·
SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1) ·
SC: 5-15 minutes; ultra-rapid Lyumjev faster (1) ·
SL/spray: 1-3 minutes; IV: minutes; patch: 30-60 minutes (1) ·
Sleep effect from first dose; antidepressant effect over 1-4 weeks (1) ·
Symptom relief within 24-48 hours of starting episodic treatment (1) ·
Symptom relief within days (1) ·
Symptomatic effect within weeks; full response by 12-24 weeks (1) ·
Topical hours; intra-articular days to weeks (1) ·
Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) ·
Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) ·
Visible lightening at 4-12 weeks (1) ·
~30 minutes (oral) (1)
duration:
None (1) ·
12-24 hours per dose (1) ·
2 weeks per dose (1) ·
2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) ·
2-4 weeks per dose (1) ·
24 hours (2) ·
24 hours (HS dosing) (1) ·
24 hours (once-daily dosing supported by long half-life) (1) ·
3-5 hours (2) ·
3-5 hours (IR); 8-24 hours (ER); 12-24 hours (epidural / intrathecal) (1) ·
30-90 minutes (infiltration without epinephrine); 90-200 minutes (with epinephrine); 12 hours (patch) (1) ·
4-6 hours (2) ·
6-8 hours (3) ·
6-8 hours (IR oral); 12-24 hours (ER) (1) ·
8 hours per oral dose (1) ·
8-12 hours (1) ·
8-12 hours (oral); 4-6 hours (IV) (1) ·
BID dosing (IR); once-daily (XR) (1) ·
Biologic 36-54 hours (long-acting) (1) ·
Biologic ~8-12 hours (short-acting) (1) ·
Hours per application (5) ·
Hours per dose (much shorter biologic effect than ergocalciferol/cholecalciferol because it is the already-active form, not the storage form) (1) ·
Hours per topical application (1) ·
Hours to days per application (1) ·
Intra-articular 3-6 months (depot effect of acetonide microcrystals) (1) ·
Monthly dosing (2) ·
Monthly or quarterly dosing (1) ·
N/A (2) ·
Once-weekly dosing in rheumatology (1) ·
Persistent activity 6+ hours (residual binding to skin and oral surfaces) (1) ·
SL: 30 minutes; patch: 12-14 hours; IV continuous (1) ·
Variable (1) ·
~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1)
halflife:
bioavailability:
pregnancy:
None (4) ·
'''Among the safest antihypertensives in pregnancy''', recommended for chronic hypertension during pregnancy and first-line for severe hypertension in preeclampsia and eclampsia'"`UNIQ--ref-0000001C-QINU`"' (1) ·
'''Considered one of the safest anticonvulsants in pregnancy''', with reassuring monotherapy registry data comparable to lamotrigine and in sharp contrast to valproate, topiramate, and carbamazepine'"`UNIQ--ref-00000021-QINU`"' (1) ·
'''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-00000022-QINU`"' (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (1) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Extensive use experience in obstetric anesthesia; broadly considered safe'"`UNIQ--ref-00000022-QINU`"' (1) ·
Generally avoided in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Generally considered safe after the first trimester; first-trimester use weighed against indication.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe in pregnancy (no systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; commonly used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Inhaled and intranasal generally considered safe; widely used in asthma in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; lispro is widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Intranasal long considered acceptable; widely used in obstetric rhinitis.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; avoid (3) ·
Limited data; generally avoided in pregnancy for the cosmetic indication of onychomycosis.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; risk-benefit case by case; pregnancy is not a strict contraindication in WHO mass drug administration programs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Older agent with substantial use experience; broadly considered safe in pregnancy'"`UNIQ--ref-00000028-QINU`"' (1) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Safe at routine fluoride levels.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Some signal for cleft lip/palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
TCA class signal; limited human data specific to doxepin.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical and vaginal generally considered safe; widely used.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical corticosteroids in pregnancy: use lowest potency and smallest area; super-potent agents like clobetasol are reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical/intranasal generally low-risk; intra-articular and high-dose injection: weigh risk individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Use when benefits outweigh; widely used at physiologic doses for adrenal insufficiency.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used in obstetric emergencies (uterine relaxation, severe hypertension) when needed; otherwise limited routine use.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used when needed for hypoparathyroidism or renal osteodystrophy in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Widely used in pregnancy for HSV/VZV indications; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (1) ·
OTC (intranasal Flonase) and [[USLegal:Prescription only|Rx-only]] (inhaled, topical) in US (1) ·
OTC (low-dose topicals) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) ·
OTC (lower-concentration washes) and [[USLegal:Prescription only|Rx-only]] (Peridex oral rinse, ChloraPrep) in US (1) ·
OTC (lowest-strength topicals) and [[USLegal:Prescription only|Rx-only]] (higher strengths, injectable) in US (1) ·
OTC (most dentifrice and rinse) and [[USLegal:Prescription only|Rx-only]] (high-concentration paste/gel, supplements) in US (1) ·
OTC (Nasonex 24HR) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (ophthalmic ointment) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (topical) and [[USLegal:Prescription only|Rx-only]] (oral) in US (1) ·
Plant unrestricted; pharmaceutical atropine Rx-only (1) ·
Rx (3) ·
[[USLegal:Over-the-counter|OTC]] for most oral and topical formulations; [[USLegal:Prescription only|Rx-only]] for injectable (1) ·
[[USLegal:Prescription only|Rx-only]] for most formulations; some low-concentration topical formulations are [[USLegal:Over-the-counter|OTC]] (4% cream) (1) ·
[[USLegal:Prescription only|Rx-only]] for oral and most topical formulations in US; Voltaren Arthritis Pain 1% gel switched to [[USLegal:Over-the-counter|OTC]] in 2020 (1) ·
[[USLegal:Prescription only|Rx-only]] in US (18) ·
[[USLegal:Prescription only|Rx-only]] in US (some OTC formulations exist) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (the veterinary preparations are not for human use) (1) ·
[[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for Clostridioides difficile colitis (one of the most C. difficile-inducing antibiotic classes)'"`UNIQ--ref-00001444-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from carisoprodol which is Schedule IV'"`UNIQ--ref-00000019-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Schedule II|Schedule II controlled substance]] in US; WHO essential medicine'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-0000002B-QINU`"' (1)
Showing below up to 46 results in range #1 to #46.